# Efficacy of N-acetylcysteine to Prevent Anti-tuberculosis Drug-induced Liver Injury: A Randomized Controlled Trial

> **NCT05738681** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Mahidol University** · enrollment: 82 (estimated)

## Conditions studied

- Tuberculosis
- Drug Induced Liver Injury
- Hepatitis

## Interventions

- **DRUG:** N acetyl cysteine

## Key facts

- **NCT ID:** NCT05738681
- **Lead sponsor:** Mahidol University
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-09-09
- **Primary completion:** 2023-03-31
- **Final completion:** 2023-05-31
- **Target enrollment:** 82 (ESTIMATED)
- **Last updated:** 2023-02-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05738681

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05738681, "Efficacy of N-acetylcysteine to Prevent Anti-tuberculosis Drug-induced Liver Injury: A Randomized Controlled Trial". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05738681. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*